Physician profile
Marc Maskowitz
NPI 1750451258
$12,558.11
in general payments reported to CMS, 2019-2025
37 companies · $55.19 in 2025
The $55.19 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,804 · 2020: $2,231 · 2021: $1,272 · 2022: $873 · 2023: $690 · 2024: $634 · 2025: $55.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.06 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $2,543.35 | 2019 | |
| Abbott Laboratories | $1,975.74 | 2019-2024 | Eterna, Proclaim |
| Medtronic USA, INC. | $1,790.50 | 2019-2020 | |
| Titan Pharmaceuticals, INC. | $1,171.19 | 2019-2020 | |
| Medtronic, INC. | $910.25 | 2021-2024 | Intellis Adaptivestim |
| Nevro Corp. | $594.38 | 2019-2020 | |
| Stimwave Technologies Incorporated | $470.26 | 2019-2020 | |
| Almatica Pharma LLC | $414.47 | 2021-2023 | Gralise |
| Collegium Pharmaceutical, INC. | $365.40 | 2019-2024 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.88 | 2019-2023 | Xifaxan, Relistor |
| Boston Scientific Corporation | $294.95 | 2021-2025 | Infinion 16, General - Pain Management |
| Assertio Therapeutics, INC. | $177.74 | 2019-2020 | |
| Mdd US Operations, LLC | $169.10 | 2019-2020 | |
| Merz North America, INC. | $146.49 | 2019-2020 | |
| Amgen INC. | $138.23 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $116.37 | 2023 | Iovera |
| Arbor Pharmaceuticals, INC. | $108.80 | 2019-2021 | |
| Relievant Medsystems, INC. | $96.43 | 2023 | Intracept |
| Si-Bone, INC. | $87.32 | 2019-2023 | |
| Radius Health, INC. | $83.76 | 2019-2024 | Tymlos |
| Abbvie INC. | $81.06 | 2022-2025 | |
| Spr Therapeutics, INC | $65.93 | 2024 | Sprint Pns System |
| Orexo US, INC. | $57.10 | 2020 | |
| Biodelivery Sciences International, INC. | $52.42 | 2019-2021 | |
| Stryker Corporation | $40.79 | 2019-2020 | |
| Grt US Holding, INC. | $39.74 | 2020-2022 | |
| Lundbeck LLC | $38.51 | 2021-2022 | |
| Pfizer INC. | $26.11 | 2019-2020 | |
| Forte Bio-Pharma LLC | $25.59 | 2021 | |
| Merz Pharmaceuticals, LLC | $25.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.56 | 2022 | |
| Novo Nordisk INC | $23.79 | 2023 | Ozempic, Rybelsus |
| Redhill Biopharma INC. | $23.05 | 2021 | |
| Siemens Medical Solutions USA, INC. | $21.51 | 2019 | |
| Allergan, INC. | $17.65 | 2020 | |
| Scilex Pharmaceuticals INC. | $17.64 | 2019 | |
| Lilly USA, LLC | $16.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Maskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.